Evidence map›Paper›PMID 37958502›Full record

ArticleInternational journal of molecular sciences2023

Comprehensive Physicochemical Characterization, In Vitro Membrane Permeation, and In Vitro Human Skin Cell Culture of a Novel TOPK Inhibitor, HI-TOPK-032.

Basanth Babu Eedara, Bhagyashree Manivannan, Wafaa Alabsi, Bo Sun, Clara Curiel-Lewandrowski, Tianshun Zhang, Ann M Bode, Heidi M Mansour

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Basanth Babu EedaraCenter for Translational Science, Florida International University, Port St. Lucie, FL 34987, USA.ORCID 0000-0002-8462-4181
Bhagyashree ManivannanCenter for Translational Science, Florida International University, Port St. Lucie, FL 34987, USA.ORCID 0000-0002-5198-8202
Wafaa AlabsiSkaggs Pharmaceutical Sciences Center, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA.
Bo SunSkaggs Pharmaceutical Sciences Center, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA.
Clara Curiel-LewandrowskiSkin Cancer Institute, The University of Arizona Cancer Center, Tucson, AZ 85724, USA.ORCID 0000-0001-8982-6252
Tianshun ZhangThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.ORCID 0000-0001-7018-8393
Ann M BodeThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.ORCID 0000-0002-7432-082X
Heidi M MansourCenter for Translational Science, Florida International University, Port St. Lucie, FL 34987, USA.ORCID 0000-0003-3993-9210
Florida International University · USUniversity of Arizona · USUniversity of Minnesota · US

Funding

Targeted Prevention for Non-Melanoma Skin CancerP01CA229112 · NCI · UNIVERSITY OF ARIZONA · PI MANSOUR, HEIDI M. · 2019 to 2023
$7.1M
NCI NIH HHS P01 CA229112NIH HHS P01CA229112
6 · The paper itself

Abstract

Nonmelanoma skin cancers (NMSC) are the most common skin cancers, and about 5.4 million people are diagnosed each year in the United States. A newly developed T-lymphokine-activated killer cell-originated protein kinase (TOPK) inhibitor, HI-TOPK-032, is effective in suppressing colon cancer cell growth, inducing the apoptosis of colon cancer cells and ultraviolet (UV) light-induced squamous cell carcinoma (SCC). This study aimed to investigate the physicochemical properties, permeation behavior, and cytotoxicity potential of HI-TOPK-032 prior to the development of a suitable topical formulation for targeted skin drug delivery. Techniques such as scanning electron microscopy (SEM), energy-dispersive X-ray (EDX) spectroscopy, differential scanning calorimetry (DSC), hot-stage microscopy (HSM), X-ray powder diffraction (XRPD), Karl Fisher (KF) coulometric titration, Raman spectrometry, confocal Raman microscopy (CRM), attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR), and Fourier transform infrared microscopy were used to characterize HI-TOPK-032. The dose effect of HI-TOPK-032 on in vitro cell viability was evaluated using a 2D cell culture of the human skin keratinocyte cell line (HaCaT) and primary normal human epidermal keratinocytes (NHEKs). Transepithelial electrical resistance (TEER) at the air-liquid interface as a function of dose and time was measured on the HaCAT human skin cell line. The membrane permeation behavior of HI-TOPK-032 was tested using the Strat-M

Indexed as

Colonic NeoplasmsSkin NeoplasmsCell Culture TechniquesHumansIndolizinesMitogen-Activated Protein Kinase KinasesQuinoxalinesIndolizinesMitogen-Activated Protein Kinase KinasesN-(12-cyanoindolizino(2,3-b)quinoxalin-2-yl)thiophene-2-carboxamideQuinoxalinesair–liquid interfacecell viabilityHaCaT cell lineNHEK cellsNMSCStrat-MTEER

Identifiers

PMID37958502
PMCPMC10650786
OpenAlexW4387906408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.